Keith Flaherty is listed as an executive officer, director, and promoter on 8 SEC Form D filings by 4 issuers between Aug 2019 and May 2025: Scorpion Therapeutics, Inc. (Boston, MA — biotechnology — 2020–2024; $147M reported sold to 38 investors), Checkmate Pharmaceuticals, Inc. (Cambridge, MA — biotechnology — 2019–2020; $85.1M reported sold to 17 investors), Antares Therapeutics, Inc. (Boston, MA — biotechnology — 2025; $40M reported sold to 35 investors) and C-REVEAL THERAPEUTICS LLC (Pembroke, MA — biotechnology — 2020).
What this means A repeat sponsor — 4 separate companies raised money with this person listed as executive officer, director, and promoter, over about 6 years. Across those companies the filings report $272.1M sold in total.
Listed alongside Alan Fuhrman (4 shared filings), Arthur Krieg (4 shared filings), Barry Labinger (4 shared filings), Charles Yon (4 shared filings), Corey Goodman (4 shared filings) and 29 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Keith. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 8 public filings for Keith Flaherty and found 6 differences: Form D filed 17 days after the first sale; 4 offerings have no amendment in the last 12 months and may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.